傑創智能(301248.SZ):擬參與產業投資基金用於對成都銥通股權投資
格隆匯6月20日丨傑創智能(301248.SZ)公佈,公司擬作為有限合夥人以自有資金200萬元,與上海圓融創業投資有限公司、自然人何曉玲、劉華、葉嵐等9人共同出資向青島圓融銥通股權投資合夥企業(簡稱“青島銥通”)進行投資,該基金總規模為1600萬元,公司認繳出資額佔比為12.5%,基金管理人為上海圓融。
本合夥企業專項用於對成都銥通科技有限公司(簡稱“成都銥通”)進行股權投資,該企業是一家專注於模擬射頻集成電路芯片定製設計服務提供商。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.